AR118085A1 - Inhibidores de enzimas - Google Patents

Inhibidores de enzimas

Info

Publication number
AR118085A1
AR118085A1 ARP200100399A ARP200100399A AR118085A1 AR 118085 A1 AR118085 A1 AR 118085A1 AR P200100399 A ARP200100399 A AR P200100399A AR P200100399 A ARP200100399 A AR P200100399A AR 118085 A1 AR118085 A1 AR 118085A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
halo
alkoxy
alkyl
independently selected
Prior art date
Application number
ARP200100399A
Other languages
English (en)
Inventor
Xuezheng Yang
Joseph William Wrigglesworth
Alun John Smith
Smith Colin Peter Sambrook
Rachael Pittaway
Iain Robert Miller
Matthew Robert Conroy
Thomas Matthew Baker
Terence Aaron Panchal
Stefano Levanto
Karamjit Singh Jandu
Paul Stuart Hinchliffe
Julie Nicole Hamblin
Erica Lee Goldsmith
Emanuela Gancia
Andrew Peter Cridland
David Edward Clark
Michael John Stocks
David Philip Rooker
Alicja Stela Obara
Alessandro Mazzacani
Sally Louise Marsh
Simon Teanby Hodgson
David Michael Evans
Hannah Joy Edwards
Rebecca Louise Davie
Mitchell Lewis Childs
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of AR118085A1 publication Critical patent/AR118085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente proporciona compuestos de fórmula (1), composiciones que comprenden dichos compuestos; el uso de dichos compuestos en terapia; y métodos para tratar pacientes con dichos compuestas; en donde R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ y R¹⁰ tienen la definición proporcionada en el presente documento. Reivindicación 1: Un compuesto de fórmula (1), donde: W, X, Y y Z se seleccionan independientemente de C y N de modo que el anillo que contiene W, X, Y y Z se selecciona de benceno, piridina, piridazina, pirimidina, pirazina y triazina; R¹, R⁴ y R⁵ están independientemente ausentes, o se seleccionan independientemente de H, alquilo, alcoxi, -CF₃, -OH, -CN, halo, -COOR¹² y -CONR¹⁴R¹⁵; cuando X es C, uno de R² y R³ es -L-V-R¹³ y el otro de R² y R³ se selecciona de H, alquilo, alcoxi, -CF₃, -OH, -CN, halo, -COOR¹² y -CONR¹⁴R¹⁵; o cuando X es N, R² es -L-V-R¹³ y R³ está ausente; R⁶, R⁷, R⁸, R⁹ y R¹⁰ se seleccionan independientemente de H, alquilo, alcoxi, -CF₃, -OH, -CN, halo, -COOR¹² y -CONR¹⁴R¹⁵; L se selecciona de un enlace, alquileno y -C(O)-; V está ausente, o seleccionado de O y NR¹²; R¹² se selecciona de H y alquiloᵇ; R¹³ es (CH₂)₀₋₃(heterociclilo); alquilo es un hidrocarburo saturado lineal que tiene hasta 4 átomos de carbono (C₁₋₄) o un hidrocarburo saturado ramificado de 3 ó 4 átomos de carbono (C₃₋₄); alquilo puede estar opcionalmente sustituido con 1 ó 2 sustituyentes seleccionados independientemente entre C₁₋₃ alcoxi, -OH, -CN, -NR¹⁴R¹⁵, -NHCOCH₃, halo, -COOR¹² y -CONR¹⁴R¹⁵; el alquiloᵇ es un hidrocarburo saturado lineal que tiene hasta 4 átomos de carbono (C₁₋₄) o un hidrocarburo saturado ramificado de 3 ó 4 átomos de carbono (C₃₋₄); el alquiloᵇ puede estar opcionalmente sustituido con 1 ó 2 sustituyentes seleccionados independientemente de -OH, -CN, -NHCOCH₃ y halo; el alquileno es un hidrocarburo saturado lineal bivalente que tiene de 1 a 4 átomos de carbono (C₁₋₄) o un hidrocarburo saturado bivalente ramificado que tiene de 3 a 4 átomos de carbono (C₃₋₄); alcoxi es un hidrocarburo lineal O-ligado de entre 1 y 3 átomos de carbono (C₁₋₃) o hidrocarburo ramificado vinculado a O de entre 3 y 4 átomos de carbono (C₃₋₄); el alcoxi puede estar opcionalmente sustituido con 1 ó 2 sustituyentes seleccionados independientemente de -OH, -CN, -CF₃, -N(R¹²)₂ y fluoro; halo es F, Cl, Br o I; heterociclilo es un anillo no aromático de 4, 5 ó 6 miembros que contiene carbono que contiene uno o dos miembros en el anillo que se seleccionan entre N, NR¹⁶ y O; heterociclilo puede estar opcionalmente sustituido con 1, 2, 3, ó 4 sustituyentes independientemente seleccionados de alquilo, alcoxi, oxo, -CF₃, -OH, -CN, halo, -COOR¹² y -CONR¹⁴R¹⁵; R¹⁴ y R¹⁵ se seleccionan independientemente de H y alquiloᵇ; R¹⁶ se selecciona de H y alquilo; y tautómeros, isómeros, estereoisómeros (incluidos enantiómeros, diastereoisómeros y mezclas racémicas y no racémicas de los mismos), isótopos deuterados y sus sales y/o solvatos farmacéuticamente aceptables.
ARP200100399A 2019-08-21 2020-02-13 Inhibidores de enzimas AR118085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2019/052359 WO2021032936A1 (en) 2019-08-21 2019-08-21 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
AR118085A1 true AR118085A1 (es) 2021-09-15

Family

ID=67777359

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100399A AR118085A1 (es) 2019-08-21 2020-02-13 Inhibidores de enzimas

Country Status (14)

Country Link
US (1) US20220363668A1 (es)
EP (1) EP4017587A1 (es)
JP (1) JP2022545158A (es)
KR (1) KR20220051207A (es)
CN (1) CN114269430A (es)
AR (1) AR118085A1 (es)
AU (1) AU2020333222A1 (es)
BR (1) BR112022000936A2 (es)
CA (1) CA3147228A1 (es)
CO (1) CO2022000266A2 (es)
IL (1) IL289783A (es)
MX (1) MX2022002069A (es)
TW (1) TW202115033A (es)
WO (2) WO2021032936A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2281885A1 (en) 2003-08-27 2011-02-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
EP2683397B1 (en) 2011-03-09 2017-08-09 CSL Behring GmbH Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
WO2017123518A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
CN109475530B (zh) 2016-05-23 2022-03-01 洛克菲勒大学 用于治疗自身免疫性疾病的氨酰基吲唑免疫调节剂
EP3541375B1 (en) 2016-11-18 2023-08-23 Merck Sharp & Dohme LLC Factor xiia inhibitors
EP3541381B1 (en) 2016-11-18 2022-12-28 Merck Sharp & Dohme LLC Inhibitors of factor xiia
CA3083938A1 (en) 2017-11-29 2019-06-06 The Rockefeller University Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases

Also Published As

Publication number Publication date
KR20220051207A (ko) 2022-04-26
WO2021032936A1 (en) 2021-02-25
IL289783A (en) 2022-03-01
MX2022002069A (es) 2022-03-17
CN114269430A (zh) 2022-04-01
AU2020333222A1 (en) 2022-02-24
EP4017587A1 (en) 2022-06-29
US20220363668A1 (en) 2022-11-17
CA3147228A1 (en) 2021-02-25
BR112022000936A2 (pt) 2022-03-08
TW202115033A (zh) 2021-04-16
WO2021032937A1 (en) 2021-02-25
CO2022000266A2 (es) 2022-01-28
JP2022545158A (ja) 2022-10-26

Similar Documents

Publication Publication Date Title
AR118085A1 (es) Inhibidores de enzimas
AR118084A1 (es) Inhibidores de enzimas
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR122019A2 (es) Compuestos tricíclicos inhibidores de la pi3k y métodos de uso
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR107694A1 (es) Heteroarilos inhibidores de pad4
AR087102A1 (es) Derivados de bencilamina como inhibidores de la calicreina plasmatica
AR102850A1 (es) Inhibidores de enzimas
MX9300256A (es) Derivados de acido acetico y proceso para su preparacion.
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR102851A1 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
CO6190523A2 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR118083A1 (es) Inhibidores de enzimas
AR092288A1 (es) Ligandos del receptor ep1
AR125425A1 (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
ES2072003T3 (es) Medio fluidocristalino.
AR062011A1 (es) Derivados de diazol y sus composiciones como inhibidores de itpkb
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR062405A1 (es) Derivados de isoindol
AR046793A1 (es) Derivados de pirazol, antagonistas del receptor de la orexina
AR118081A1 (es) Inhibidores de enzimas
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
AR123848A1 (es) Compuestos espiro heterocíclicos y métodos de uso
AR117539A1 (es) INHIBIDORES DE TGF-bR1 (ALK5) ÚTILES PARA TRATAR TRASTORNOS DE PROLIFERACIÓN CELULAR